Show simple item record

Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know?

dc.contributor.authorPrevidi, MC
dc.contributor.authorCarotenuto, P
dc.contributor.authorZito, D
dc.contributor.authorPandolfo, R
dc.contributor.authorBraconi, C
dc.date.accessioned2016-11-23T13:09:56Z
dc.date.issued2017-02-01
dc.identifier.citationFuture oncology (London, England), 2017, 13 (5), pp. 443 - 453
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/248
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2016-0253
dc.description.abstractPancreatic cancer is an aggressive cancer of the digestive system, which is becoming a serious health problem worldwide. Overall survival for patients with pancreatic cancer is poor, mainly due to a lack of biomarkers to enable early diagnosis and a lack of prognostic markers that can inform decision-making, facilitating personalized treatment and an optimal clinical outcome. ncRNAs play an important role in pancreatic carcinogenesis. Here we review the literature on the role of ncRNAs as biomarkers in pancreatic cancer. We focus on the significance of ncRNAs as markers for early diagnosis, as prognostic biomarkers able to inform clinical management and as targets for novel therapeutics for patients with pancreatic cancer.
dc.formatPrint-Electronic
dc.format.extent443 - 453
dc.languageeng
dc.language.isoeng
dc.publisherFUTURE MEDICINE LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectAdenocarcinoma
dc.subjectPancreatic Neoplasms
dc.subjectMicroRNAs
dc.subjectRNA, Messenger
dc.subjectRNA, Untranslated
dc.subjectPrognosis
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectGenetic Therapy
dc.subjectRNA, Long Noncoding
dc.subjectBiomarkers, Tumor
dc.titleNoncoding RNAs as novel biomarkers in pancreatic cancer: what do we know?
dc.typeJournal Article
rioxxterms.versionofrecord10.2217/fon-2016-0253
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFuture oncology (London, England)
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsNot known
icr.researchteamSignal Transduction & Molecular Pharmacology
dc.contributor.icrauthorCarotenuto, Pietro
dc.contributor.icrauthorBraconi, Chiara


Files in this item

Thumbnail
Name:
Previdi fon-2016-0253.pdf
Size:
1.132Mb
Format:
PDF
Description:
Published version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0